FDA clears GRI Bio’s Phase 2 trial of natural killer T-cell targeted therapy
The U.S. Food and Drug Administration (FDA) has given GRI Bio the green light to conduct a Phase 2 trial of its investigational natural killer T-cell (NKT)-targeted therapy, GRI-0621, in people with idiopathic pulmonary fibrosis (IPF). With the clearance of its investigational new drug (IND) application, the company…